Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
BioMarin treats rare inherited diseases — where patients are few and no treatment existed at all.
The rare disease market works unlike the ordinary one: patients number in thousands rather than millions, but there are no competitors and a course costs hundreds of thousands. Diagnosis is genetic, so a patient can be found directly and no large sales force is needed.
The main product of recent years is a drug for achondroplasia, a bone growth disorder in children: it lets a child grow closer to normal, and treatment lasts years. The rest of the portfolio is enzyme replacement therapy for other rare syndromes. Risks: insurer decisions on covering expensive treatment, competition and trial outcomes. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
BioMarin Pharmaceutical Inc. (BMRN) is a company in the Health care sector; its shares trade on Nasdaq.
The price of BioMarin Pharmaceutical Inc. (BMRN) on October 30, 2026 is 58.17 $, +1.18 % on the day. Over 52 weeks the stock traded between 49.26 $ and 70.98 $; the price now sits 41 % of the way up that range. Over the past year the price changed by +3.27 %. The P/E ratio is 154.28, which is above the sector median (24.61). Market capitalization is 11.26 billion $, rank 22 among 380 stocks of the same industry with a known capitalization.
BioMarin Pharmaceutical Inc. trades on Nasdaq under the ticker BMRN. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks BMRN has traded between 49.26 $ and 70.98 $. As of 30 October 2026 the price stood 24.95 % of the way from the 52-week low to the high.
Over one year BMRN shares rose 3.27 %; over six months they rose 0.07 %. Volatility over 90 days is 28.35 %. Dividends are not included: this is price change only, as of 30 October 2026.
BMRN trades at a price-to-earnings ratio of 154, above the sector median of 24.6. Price to sales is 3.3, below the sector median of 3.6. Price to book is 1.8, below the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
BioMarin Pharmaceutical Inc. reported revenue of 3.4B $ and net income of 73M $ over the last four quarters. Net margin is 2.14 %. Revenue changed by +11.20 % year over year. Earnings per share are 0.38 $. Market capitalisation is 11.3B $.
BMRN has a return on equity of 1.15 %, above the sector median of −40.58 %. Return on assets is 0.62 %, above the sector median of −30.08 %. Operating margin is 4.38 %, above the sector median of −20.96 %.